PI-88 News
Most Popular PI-88 Story
Progen lung cancer therapy flunks Phase II
Progen Pharmaceuticals disappointed its investors with news this morning that its experimental therapy, PI-88, failed a mid-stage trial for lung cancer. The trial, which combined the experimental... Read more...
Latest Headlines
- July 24, 2008
- September 24, 2007
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
